Amgen launches osteoporosis drug Evenity in US at annual list price of $21 900

Amgen announced Monday that it will make its osteoporosis drug Evenity (romosozumab-aqqg) available in the US at a list price of $1825 per dose, or $21 900 for a full 12-month course of injections. Murdo Gordon, executive vice president of global commercial operations at Amgen, said "we priced this product so that it is clearly a better value than existing agents that build bone."

According to Amgen, a full course of the sclerostin inhibitor, approved by the FDA last week to treat osteoporosis in postmenopausal women at high risk of fracture, is 34 percent to 74 percent lower than existing anabolic agents, such as Eli Lilly's Forteo (teriparatide) and Radius Health's Tymlos (abaloparatide), which are taken in daily doses over longer periods lasting 18 months to two years.

Gordon estimated that "only 20 percent of women who have experienced a fracture receive any type of osteoporosis treatment post-fracture," saying the disease is a largely under-diagnosed and under-treated partly because it is not a symptomatic. "This is unacceptable for the millions of women who have suffered from an osteoporosis-related fracture," he said.

Analysts have projected that Evenity, which Amgen co-develops with UCB, will generate annual sales of $274 million by 2024, while Amgen's older osteoporosis drug Prolia (denosumab) is forecast to reach $3.3 billion by 2024. 

To read more Top Story articles, click here.